title: [The prospective study on application of parenteral nutrition with alanyl-glutamine dipeptide in chemotherapy of gastrointestinal neoplasms patients].
abstract: OBJECTIVE
  There is an argument on whether or not glutamine-supplemented parenteral nutrition is beneficial to chemotherapy in gastrointestinal neoplasm patients. The aim of this study was to prospectively evaluate the effect of parenteral nutrition with alanyl-glutamine dipeptide on gastrointestinal neoplasm patients receiving chemotherapy.
  
  
  METHODS
  This study was a prospective, randomized double-blind clinical trial. Seventy-two patients were randomly divided into study group and control group (each group had 36 patients). The side effects during chemotherapy were observed. Serum albumin, serum pre-albumin, IgG, IgA, IgM, C3, C4 level were measured before chemotherapy and on day 4 and day 8 after chemotherapy. Nitrogen balance was also calculated simultaneously.
  
  
  RESULTS
  (1) Less side effects during chemotherapy in study group were revealed compared to those in control group (P<0.05). (2) Serum albumin and pre-albumin levels were both decreased in the two groups on day 4 after chemotherapy, and were markedly decreased in control group on day 8 after chemotherapy (P<0.05). (3) IgG, IgM, IgA levels were all decreased compared with the test results before chemotherapy on day 4 after chemotherapy in two groups, and were significantly decreased in control group on day 8 after chemotherapy (P<0.05). C3 and C4 levels were higher in study group compared with control group on day 8 after chemotherapy (P<0.05). (4) Nitrogen balance in study group was better than that in control group (P<0.05) on day 8 after chemotherapy.
  
  
  CONCLUSIONS
  Alanyl-glutamine dipeptide is beneficial to chemotherapy in gastrointestinal neoplasm patients. It could reduce the side effects of chemotherapy, which helps to improve the nutritional status, the immune function and the survival quality of patients during chemotherapy.
authors.affiliation: Southwest Hospital, The Third Military Medical University, Chongqing, 400038, P. R. China.
authors.forename: Yi-Liang
authors.initials: YL
authors.lastname: Peng
authors.forename: Qian-Fen
authors.initials: QF
authors.lastname: Gong
authors.forename: Zi-Qiang
authors.initials: ZQ
authors.lastname: Wand
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003110:Colonic Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D003176:Complement C3 / Q000378:metabolism; D003181:Complement C4 / Q000378:metabolism; D004151:Dipeptides / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D005472:Fluorouracil / Q000008:administration & dosage; D006801:Humans; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007075:Immunoglobulin M / Q000097:blood; D002955:Leucovorin / Q000008:administration & dosage; D008297:Male; D008875:Middle Aged; D009584:Nitrogen / Q000378:metabolism; D010288:Parenteral Nutrition; D011228:Prealbumin / Q000378:metabolism; D011446:Prospective Studies; D012004:Rectal Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D012709:Serum Albumin / Q000378:metabolism; D013274:Stomach Neoplasms / Q000097:blood / Q000188:drug therapy / Q000276:immunology / Q000628:therapy*; D055815:Young Adult
chemical_list: D003176:Complement C3; D003181:Complement C4; D004151:Dipeptides; D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007075:Immunoglobulin M; D011228:Prealbumin; D012709:Serum Albumin; D009584:Nitrogen; D002955:Leucovorin; D005472:Fluorouracil; C054122:alanylglutamine